Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
74 studies found for:    ovarian,cancer,PARP
Show Display Options
Rank Status Study
1 Completed BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Condition: Ovarian Cancer
Intervention: Drug: BMN 673 (talazoparib)
2 Active, not recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
3 Withdrawn Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Olaparib
4 Active, not recruiting POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Drug: BMN 673
5 Active, not recruiting
Has Results
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
6 Not yet recruiting A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Cediranib;   Drug: Olaparib
7 Recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
8 Recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Olaparib;   Drug: Tremelimumab
9 Completed A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: BSI-201
10 Completed A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: BSI-201
11 Active, not recruiting
Has Results
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AZD2281;   Drug: Liposomal Doxorubicin
12 Active, not recruiting Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ovarian Epithelial Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Veliparib
13 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
14 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Floxuridine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
15 Recruiting Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
16 Completed Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
17 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
18 Recruiting Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasm
Interventions: Other: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel
19 Recruiting Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Bevacizumab
20 Recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
Conditions: Breast Cancer;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Olaparib;   Drug: AZD2014;   Drug: AZD5363

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.